Dendritic cell ( DC ) ± mediated cancer immunotherapy is a very promising alternative approach to cancer treatment. In a previous study, we successfully transfected bone marrow ± derived dendritic progenitors ( BMDDPs ) with a T7 vector Ð a nonviral, cytoplasmic -based autogene expression system Ð encoding a model tumor antigen, firefly luciferase, and subsequently stimulated the transfected cells to differentiate into DCs. When injected into experimental mice, those DCs generated a strong immune response against tumor cells bearing luciferase, which not only prevented occurrence of metastasis but also eradicated existing tumors. In the present study, we constructed a T7 vector encoding mouse tyrosinase, a well -known melanoma associated tumor antigen, and used it to transfect BMDDPs. Reverse transcriptase polymerase chain reaction and Western analysis confirmed the expression of tyrosinase by DCs differentiated from transfected BMDDPs. Two immunizations of these DCs at a dose of 2Â10 6 of each successfully prevented tumor growth. More importantly, one injection of 2Â10 6 of these DCs into mice followed by five doses of recombinant human interleukin -2 administration effectively eradicated existing tumors as indicated by pulmonary metastasis assay.
D
endritic cells ( DCs ) are professional antigen -presenting cells that play a vital role in stimulating immune responses. Because they express both major histocompatibility complex (MHC ) classes I and II and costimulatory and adhesive molecules necessary for antigen presentation, DCs can not only activate naõ Ève CD4 + T helper cells, but also stimulate unprimed CD8 + cytotoxic T lymphocytes. 1 ± 4 Because of these capabilities, DCs have been widely studied as antigen-presenting cells for cancer immunotherapy. DCs can be loaded with tumor-associated antigens (TAA ) by pulsing them with whole TAA protein or TAA peptides. When introduced into experimental animals, TAA -loaded DCs initiated immune responses against the TAA -expressing cells. 5 ± 7 Recently, clinical trials have been initiated based on this pulsing technology. 8 To increase the TAA loading efficiency, DCs can also be loaded with TAAs by TAA gene transfer. 9 ± 11 In addition to increased TAA loading efficiency, other advantages of TAA gene transfer into DCs include prolonged TAA presentation and more efficient MHC class I presentation, which activates cytotoxic T lymphocytes and stimulates broader immune responses. However, DCs are primary cultured cells, which have demonstrated difficulty as recipients in gene transfer with plasmid DNA, and even when successfully transfected, the level of transgene expression is relatively low. 12 ± 14 To increase the gene transfer efficiency, viral vectors, including adenovirus, retrovirus, and vaccina, encoding TAA genes have been used. 15 ± 18 Despite elevated gene transfer efficiency, the use of viral vectors for DC transduction has some pitfalls. For example, because DCs are differentiated nondividing cells, the use of retrovirus vector is limited. Although adenovirus vectors and vaccina virus vectors can be used to transduce nondividing cells, their use in DCmediated immunotherapy results in immune responses against the vectors themselves, which prevents adequate expression of the antigen in subsequent administrations.
Recently, we have developed a DC gene transfer system using a T7 vector. 19 The T7 vector is a plasmid DNA -based, cytoplasmic autogene expression system. 20 In our previous study, instead of directly transfecting matured DCs, bone marrow ± derived dendritic progenitors ( BMDDPs ) were transfected with the T7 vector encoding firefly luciferase as a reporter gene and a model tumor antigen. High levels of luciferase activity were detected from DCs differentiated from the transfected BMDDPs. When injected into experimental mice, the DCs stimulated a strong immune response against murine B16 F0 melanoma tumor cells genetically engineered to express luciferase, which not only prevented the tumor from growing in vivo but also eradicated existing experimental tumors. 19 To further explore the potential of T7 system in cancer immunotherapy, in the present study, a cDNA sequence encoding murine melanoma -specific TAA, tyrosinase, was built into the T7 vector and BMDDPs were transfected with the T7 / tyrosinase vector. Pulmonary metastasis assay demonstrated that both preventive and therapeutic effects on tumor growth were achieved using this T7 vector approach.
MATERIALS AND METHODS

Construction of pT7T7 / T7Tyr plasmid
Plasmid pT7T7 /T7Tyr was constructed as described previously 20 with minor modifications. Briefly, mouse tyrosinase cDNA sequence was amplified by polymerase chain reaction ( PCR ) from clone MTY811C (ATCC no. 63164 ) and inserted into the pTM-1 vector under the control of a T7 promoter (pT7 ) . 21 The resulting plasmid is designated as pT7Tyr. The PCR primers were designed to ensure that tyrosinase translation uses the ATG start codon provided in the pTM -1 vector. Then a fragment containing the T7 promoter, tyrosinase cDNA sequence, T7 transcription terminator, and bovine polyadenylation signal was cut out from pT7Tyr and inserted into the BstZ1 site of the pT7T7 plasmid, resulting in the plasmid pT7T7 /T7Tyr. 20 The critical sequences of pT7T7 /T7Tyr (Fig 1 ) were verified by automatic DNA sequencing ( 310 DNA Analyzer, PE, Foster City, CA) .
DC culture and transfection
Bone marrow cells were isolated from female C57BL /6J mice as described previously. 19 Briefly, bone marrow cells were flushed from the femur and tibia with RPMI 1640 / HEPES medium ( Gibco BRL, Grand Island, NY ) containing 100 g/ mL of gentamicin and passed through a 40-m cell strainer. The cells were then centrifuged at 500Âg at room temperature for 5 minutes. The red blood cells in the cell preparation were lysed by suspending the cell pellet obtained from each mouse in 2.5 mL of ACK lysing solution (0.15 M of NH 4 Cl, 1 mM KHCO 3 , and 0.1 mM Na 2 EDTA, pH 7.3) and incubating at room temperature for 5 minutes. After centrifugation, the cell pellet was suspended in modified DC culture medium ( RPMI1640, 10% fetal bovine serum, 800 IU / mL of murine GM -CSF ( Sigma, St. Louis, MO ) and 1000 IU / mL of murine interleukin -4 ( IL -4, Sigma, St. Louis, MO) and cultured in a six -well plate (cells from one mouse were seeded into two wells ). After 18 hours, the nonadherent cells were washed away with phosphatebuffered saline ( PBS ) and the remaining adherent cells were transfected with pT7T7 /T7Tyr. For transfection, the adherent bone marrow cells were rinsed twice with Dulbecco's modified Eagle's medium and incubated with a LipofectAmine (Gibco BRL, Grand Island,
in 1 ml DMEM /well) for 3 hours. After transfection, the cells were washed twice and fed with fresh DC medium. Forty -eight to 72 hours after transfection, the nonadherent DCs were harvested for expression assay or for injection into mice.
Fluorescent -activated cell sorting ( FACS ) analysis
The surface marker expression of bone marrow cells and bone marrow ±derived DCs was analyzed by FACS ( FACSCalibur, Becton Dickinson, San Jose, CA ) . Briefly, cells were washed twice, resuspended in staining buffer ( PBS containing 0.1% bovine serum albumin, 0.1% NaN 3 ) containing the appropriate antibodies, and incubated on ice for 30 minutes. After removal of the free antibodies by washing twice with the staining buffer, the stained cells were analyzed by FACSCalibur with CellQuest software ( Becton Dickinson ). The antibodies used in this study were all purchased from PharMingen (San Diego, CA ) including rat
-FITC, and CD11c-PE.
Reverse transcriptase ( RT ) PCR
Forty -eight hours after transfection, total RNAs were isolated using TRIzol Reagent ( Gibco BRL ) according to the manufacturer's protocol. One microgram of total RNA from each sample was treated with DNase I ( Gibco BRL ) and RT-PCR was performed using the Access RT-PCR System from Promega ( Madison, WI ) . Two hundred nanograms of DNase I± treated RNA was used in each reaction. The primers for the mouse tyrosinase gene were: 5 H -CCTAACTTACTCAGCCCAGC -3 H and 5 H - Figure 1 . The pT7T7 / T7Tyr vector. This vector contains a T7T7 autogene encoding a T7 RNAP gene driven by a pT7 and a murine tyrosinase cDNA sequence driven by a second pT7. Two internal ribosome entry sites were inserted between the pT7 and T7 RNAP or tyrosinase serving as a cap -independent sequence in translation for both T7 RNAP and tyrosinase. A bacterial LacI gene and an operator sequence were also inserted into the vector to reduce the toxicity associated with T7 RNAP gene expression in Escherichia coli.
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Western blot
Forty -eight hours after transfection, cells were lysed with lysing buffer ( 50 mM Tris ±HCl, pH 6.8, 1% sodium dodecyl sulfate, 1% -mercaptoethanol, 0.1 M DTT, 5% sucrose, and 100 M Na orthovanadate ) and 20 L of the cell lysates was loaded onto a 7.5% sodium dodecyl sulfate polyacrylamide gel for electrophoresis. After electrophoresis, the proteins were transferred onto a nitrocellulose membrane. Nonspecific binding was blocked by incubating the membrane in 5% nonfat dry milk in washing buffer, TBS (10 mM Tris, pH 7.4, 75 mM NaCl, 0.1% Tween -20, and 1 mM EDTA ) for 2 hours at room temperature. The membrane was then incubated with goat antimouse tyrosinase antibody (#RDI -RTTYROSINabG, Research Diagnostics, Flanders, NJ ) at a concentration of 0.5 g /mL in blocking buffer for overnight at 48C. After three 5 -minute washes with TBS plus 0.05% Tween -20, the membrane was incubated with horseradish peroxidase ± conjugated antigoat IgG ( RDI -705035147, Research Diagnostics ) at a concentration of 1:5000 dilution for 1 hour at room temperature. After four 5 -minute washes with TBS plus 0.05% Tween -20, tyrosinase was detected using ECL system (RPN -2106, Amersham Pharmacia, Piscataway, NJ ).
Detection of interferon -(IFN-) ± producing T cells
To test whether an immune response is generated after vaccination of T7T7 /T7Tyr-transfected DCs, an IFNtest was performed. Briefly, two groups of mice ( four for each ) were intravenously ( i.v. ) injected with 2Â10 6 empty DCs or 2Â10 6 T7T7 /T7Tyr-transfected DCs, respectively, followed by five doses of human recombinant interleukin -2 (IL -2 ) at a dose of 10,000 IU mouse À 1 day À 1 for 5 days. Two weeks after vaccination, splenocytes were isolated from the mice and T cells were enriched by nylon wool purification. The purified T cells were stimulated in vitro with B16F0 tumor cell lysate plus anti -CD28 and anti -CD49d antibodies ( PharMingen) at 378C for 2 hours. After stimulation, protein transport inhibitor, GolgiPlug ( PharMingen ), was added and incubated for 4 hours. Then cell surface and intracellular stainings were performed according to the procedures provided with the Cytofix /Cytoperm Kit ( PharMingen) followed by FACS analysis.
Pulmonary metastasis assay
All animals used in this study were 6 ±8 -week -old female C57BL /6J mice from Jackson Laboratories (Bar Harbor, ME ). For the preventive study, four groups of five mice were i.v. injected with PBS, 2Â10 6 DCs, 2Â10 6 DCs transfected with pT7T7 /T7Luc, or 2Â10 6 DCs transfected with pT7T7 /T7Tyr, respectively. One week later, the mice received a second dose of the same vaccine. One week after the second vaccine, all the mice were injected i.v. with 0.75Â10 6 B16F0 mouse melanoma tumor cells (ATCC no. CRL -6322) . Four weeks after tumor cell inoculation, mice were sacrificed and tumor nodules on the lungs and tumors in pulmonary cavities were examined. For therapeutic study, mice were injected with tumor cells 3 days before the injection of PBS, DCs, DCs transfected with pT7T7 / T7Luc, or DCs transfected with pT7T7 / T7Tyr. After vaccination, all the mice were given five intraperitoneal (i.p. ) doses of human recombinant IL-2 (Gibco BRL ) at a dosage of 10,000 IU mouse À 1 day À 1 . Four weeks after tumor challenge, the mice were examined for tumor nodules on the lungs and tumors in pulmonary cavities. A standard Student's t test was used for the statistical analysis. To test the specificity of the immune response generated, a nontyrosinaseexpressing tumor cell line, TC -1 (a kind gift from T.C. Wu, John Hopkins University ), was used in two groups of the study.
CD4 and CD8 T -cell depletion study
To test the nature of the antitumor immune responses generated by the T7 system, a T-cell depletion experiment was performed. On day 1, three groups of mice (five for each ) were i.v. injected with 0.75Â10 6 B16F0 cells. On day 2, the three groups of mice were i.p. injected with 1 mg / mouse of rat IgG, rat antimouse CD4 ( GK1.5, L3T4, PharMingen ), or rat antimouse CD8 ( Ly-2, PharMingen) , respectively. On day 4, all the 15 mice received 2Â10 6 pT7T7 /T7Tyr-transfected DCs followed by five doses of IL -2 treatment. FACS analysis showed that the depletion is very efficient ( data not shown ).
RESULTS
Transfected BMDDP can be stimulated to differentiate to DCs
Our previous studies have shown that it is very difficult to directly transfect mature DCs with the T7 vector. Instead of transfecting mature DCs, in this study, BMDDPs were transfected with pT7T7 / T7Tyr. To confirm that the transfected BMDDPs can still be stimulated to differentiate to functional DCs, flow cytometry was used to detect the surface markers for DCs 48 hours after transfection. Flow cytometric analysis of these cells indicated that these cells expressed typical DC surface markers: MHC -I (H -2D b and H -2K b ), MHC-II (I-A b ), CD80, CD86, and CD11c. In contrast, fresh bone marrow cells express only MHC -I and CD80, but not MHC -II, CD86, nor CD11c (Fig 2 ) .
DCs differentiated from transfected BMDDPs express tyrosinase
To test whether the new T7 vector, pT7T7 /T7Tyr, can be expressed by DCs 48 hours after transfection, total RNAs and proteins were isolated from DCs differentiated from BMDDPs, transfected with pT7T7 /T7Tyr, and nontransfected DCs. Total RNA and protein from nontransfected B16F0 cells were also prepared and served as positive controls. RT-PCR and Western blotting analyses were performed using specific mouse tyrosinase primers and antibody, respectively. The results (Fig 3A  and B ) . Figure 5 . Representative lung metastasis. A: Mice were vaccinated with DCs expressing murine tyrosinase twice in a 1 -week interval. One week after the second vaccination, 1Â10 6 B16F0 cells were injected i.v. 28 days later, the mice were sacrificed, lungs were isolated and fixed, and the tumor nodules were counted under a stereomicroscope. Shown is a representative lung from a control mouse ( left ) and a representative lung from immunized mouse ( right ) . B: Mice were injected i.v. with 1Â10 6 B16F0 cells. Three days later, the mice were injected i.v. with 2Â10 6 DCs / mouse and followed by five doses of IL -2 i.p. injection ( 10,000 IU day À 1 mouse À 1 ) . Twenty -eight days after the tumor cell injection, the mice were sacrificed, lungs were isolated and fixed, and the tumor nodules were counted under a stereomicroscope. Picture shows a representative lung from control mouse ( left ) and a representative lung from a DC -treated mouse ( right ) .
pT7T7 / T7Tyr -transfected DC vaccine activated both CD4 and CD8 T cells
To determine if the T7 system can stimulate antigenspecific immune response, a T cell IFN -production assay was performed. As shown in Figure 4 , pT7T7 / T7Tyr-transfected DC vaccine significantly increased Tcell populations that secrete IFN -. The CD4 and CD8 T cells that express IFN -in empty DC -treated mice are 0.02 0.01% and 0.026 0.01%, respectively, whereas the corresponding numbers in pT7T7 /T7Tyr-transfected DCtreated mice are 0.154 0.053% and 0.156 0.034%, respectively.
DCs expressing murine tyrosinase stimulate immune responses against experimental melanoma in vivo
To determine whether DCs differentiated from BMDDP transfected with pT7T7 /T7Tyr can stimulate melanoma tumor cell -specific immune responses, pulmonary metastasis assays were performed in this study in two ways: preventive treatment and therapeutic treatment. Table 1 and Figure 5 show that the injection of 2Â10 6 BMDDPderived DCs transfected with the T7 vector almost completely prevented the growth of the very aggressive mouse melanoma tumor cells and effectively eradicated the existing tumors. The nontransfected DCs or mock ( pT7T7 /T7Luc ) transfected DCs did not stimulate any tumor-specific immune responses. Human recombinant IL -2 alone did not show any antitumor effect (Table 1) . In addition to the lung tumor nodules, most of the control mice developed metastases elsewhere in the body such as in the pulmonary cavity, peritoneal cavity, neck, etc., whereas such metastases were not observed in any of the DC immunized animals. More importantly, the treatment of pT7T7 /T7Tyr-transfected DCs did not show any antitumor effect against a nontyrosinase expressing tumor line, TC -1 ( Table 2 ) .
Both CD4 and CD8 T cells are required for the immune responses generated by pT7T7 / T7Tyr vaccine
To test the nature of the antitumor immune responses generated by pT7T7 / T7Tyr-transfected DCs, CD4 or CD8 T cells were depleted by antibody injection. As shown in Table  3 , depletion of CD4 T cells or CD8 T cells almost completely abolished the antitumor effects generated by the pT7T7 / T7Tyr-transfected DC injection compared to the rat IgG injection. This result demonstrated that the antitumor immune responses generated by the T7 system require both CD4 and CD8 T cells.
DISCUSSION
Although DCs can be isolated and differentiated from different tissues, in most cases, they are nondividing cells. This characteristic of DCs limits the use of retrovirus vectors as gene transfer vehicles. Adenovirus vectors and vaccinia virus vectors work well on nondividing cells, but their utility in cancer immunotherapy is limited because they can initiate immune responses against the vectors themselves, which will interfere with later treatment with the same vector. 22 Transfection of DCs with common naked plasmid DNAs encoding TAAs has demonstrated to be difficult and the transgene expression level is relatively low.
12 ± 14 However, a recently developed T7 system is a good candidate for TAA gene delivery into DCs. 20, 23 The T7 vector has several advantages in DC -mediated cancer immunotherapy. First, the T7 system is a nucleus-independent gene expression system; transgenes are expressed in the cytoplasm, thus, the technique works very well in nondividing cells. Second, the T7 system is an autogene expression system; once the expression of the T7 RNAP gene is initiated, the T7 RNAP will drive expression of the gene of interest (tyrosinase in this study ) as well as the T7 RNAP gene. Consequently, the production of T7 RNAP, and thus the TAA, is self -regulated, leading to efficient and high level of expression.
Tyrosinase has been identified as a TAA for melanoma. 18, 24, 25 In this study, murine tyrosinase cDNA was built into the T7 vector ( Fig 1 ) and the expression of the gene was confirmed by RT-PCR and Western blot analysis ( Fig 3A and B ) . There is no apparent toxicity to DC observed in vitro. Although we do not have direct evidence that peptides of murine tyrosinase were presented on the cell surface by mature DCs, the following considerations could serve as indirect evidence supporting presentation. Brisson et al 26 systemically studied the performance of the T7 system in a cytoplasm and found that proteins expressed by T7 system are normally processed in cytoplasm. If an antigen is synthesized endogenously, the antigen will be processed and presented by MHC class I molecules. 27 A FACS -mediated IFN -assay indicated that a T-cell ± mediated immune response has been generated by pT7T7 /T7Tyr-transfected DC vaccine ( Fig 4) . To determine if tyrosinase -expressing DCs can stimulate antitumor immune responses, a pulmonary metastasis assay using the murine melanoma tumor cell line, B16F0, was performed to study both the preventive and therapeutic effects. In a modification of our previous study, instead of using transgene -expressing DCs to boost the immune reaction, in this study human recombinant IL -2 was used to boost the initial immune reaction. As summarized in Table 1 , the injections of DCs from BMDDPs transfected with pT7T7 /T7Tyr followed by five doses of IL -2 effectively eradicate existing tumors (Fig 5) . This study also demonstrated that both CD4 and CD8 T cells are needed to generate the antitumor immune responses ( Table 3 ) and that the antitumor immune responses are antigen-specific ( Table 2 ) .
CONCLUSION
This study demonstrates the utility of the T7 autogene system in the expression of tyrosinase, a key melanoma marker, by mature DC. The efficient and high -level expression of tyrosinase by DC contributes to a strong immune response against tyrosinase-expressing B16F0 melanoma target cells in vivo. Moreover, the DC -mediated immune response is significant, able to eradicate preexisting tumors, as well as prevent tumor formation upon challenge with melanoma cells. The results described here, consistent with our previous studies, 19 provide encouraging evidence that the T7 expression system may be more widely applicable as an antitumor therapy. We are currently investigating the therapeutic values of the T7 system by using a number of other TAAs and also trying other transfected DC delivery methods, such as subcutaneous injection. Although our current gene transfer efficiency (percentage of transgene expressing cells) is still low ( 3± 5% ), with some improvement of gene delivery methods such as the use of particle bombardment techniques, ultimately, the T7 expression system may prove to be a very effective therapy in the treatment of several human cancers.
